Page 131 - 2020年1月第31卷第2期

low-ering GLP1R variant protective for coronary heart dis- necessary for normal insulin secretory granule biogenesis
ease[J]. Sci Transl Med，2016，8（341）：341ra76. in metabolically stressed B cells[J]. J Clin Invest，2014，
[ 7 ] ENYA M，HORIKAWA Y，IIZUKA K，et al. Association 124（10）：4240-4256.
of genetic variants of the incretin-related genes with quan- [19] FLOREZ JC，MANNING AK，DUPUIS J，et al. A 100k
titative traits and occurrence of type 2 diabetes in Japa- genome-wide association scan for diabetes and related
nese[J]. Mol Genet Metab Rep，2014，28（1）：350-361. traits in the Framingham Heart Study：replication and inte-
[ 8 ] LI P，TIWARI HK，LIN WY，et al. Genetic association gration with other genome-wide datasets[J]. Diabetes，
analysis of 30 genes related to obesity in a European 2007，56（12）：3063-3074.
American population[J]. Int J Obes：Lond，2014，38（5）： [20] BEINBORN M，WORRALL CI，MCBRIDE MW，et al. A
724-729. human glucagon-like peptide-1 receptor polymorphism re-
[ 9 ] SATHANANTHAN A，MAN CD，MICHELETTO F，et al. sults in reduced agonist responsiveness[J]. Regul Pept，
Common genetic variation in GLP1R and insulin secre- 2005，130（1/2）：1-6.
tion in response to exogenous GLP-1 in nondiabetic sub- [21] DE LUIS DA，BALLESTEROS M，LOPZ GUZMAN A，
jects：a pilot study[J]. Diabetes Care，2010，33（9）：2074- et al. rs6923761 gene variant in glucagon-like peptide1 re-
2076. ceptor：allelicfrequencies and influence on cardiovascular
[10] SCOTT RA，FREITAG DF，LI L，et al.A genomic ap- risk factors in a multicenter study of Castilla-Leon[J].
proach to therapeutic target validation identifies a glu- Clin Nutr，2018，37（6 Pt A）：2144-2148.
cose-lowering GLP1R variant protective for coronary [22] DE LUIS DA，ALLER R，IZAOLA O，et al. Role of
heart disease[J]. Sci Transl Med，2016. DOI：10.1126/sci- rs6923761 gene variant in glucagon-like peptide 1 recepto-
translmed.aad3744. rin basal GLP-1 levels，cardiovascular risk factor and seru-
[11] DE LUIS DA，DIAZ SOTO G，IZAOLA O，et al. Evalua- madipokine levels in naive type 2 diabetic patients[J]. J
tion of weight loss and metabolic changes in diabetic pa- Endocrinol Invest，2015，38（2）：143-147.
tients treated with liraglutide，effect of rs 6923761 gene [23] VIVEROS MP，DE FONSECA FR，BERMUDEZ-SILVA
variant of glucagon-like peptide 1 receptor[J]. J Diabetes FJ，et al. Critical role of the endocannabinoid system in
Complicationsm，2015，29（4）：595-598. the regulation of food intake and energy metabolism，with
[12] SADEGHIAN M，RAHMANI S，MANSOORI A. G1359A phylogenetic，developmental，and pathophysiological im-
variant of the cannabinoid receptor gene（rs1049353）and plications[J]. Endocr Metab Immune Disord Drug Targets，
obesity-related traits and related endophenotypes：a me- 2008，8（3）：220-230.
ta-analysis[J]. Ann Nutr Metab，2018，73（1）：76-85. [24] MILLER LK，DEVI LA. The highs and lows of cannabi-
[13] DE LUIS DA，OVALLE HF，SOTO GD，et al. Role of ge- noid receptor expression in disease：mechanisms and their
netic variation in the cannabinoid receptor gene（CNR1） therapeutic implications[J]. Pharmacol Rev，2011，63（3）：
（G1359A polymorphism）on weight loss and cardiovascu- 461-470.
lar risk factors after liraglutide treatment in obese patients [25] GADZICKI D，MULLER-VAHL K，STUHRMANN M. A
with diabetes mellitus type 2[J]. J Investig Med，2014，62 frequent polymorphism in the coding exon of the human
（2）：324-327. cannabinoid receptor（CNR1）gene[J]. Mol Cell Probes，
[14] BULLOCK BP，HELLER RS，HABENER JF. Tissue dis- 1999，13（4）：321-323.
tribution of messenger ribonucleic acid encoding the rat [26] DE LUIS DA，GONZALEZ M，ALLER R，et al. Relation
glucagon-like peptide-1 receptor[J]. Endocrinology，1996， of G1359A polymorphism of the cannabinoid receptor
137（7）：2968-2978. gene with metabolic syndrome ATP Ⅲ classification[J].
[15] URUSOVA IA，FARILLA L，HUI H，et al. GLP-1 inhibi- Diabet Metab Res Rev，2011，27（5）：506-511.
tion of pancreatic islet cell apoptosis[J]. Trend Endocrinol [27] ABERLE J，FEDDERWITZ I，KLAGES N，et al. Genetic
Metab，2004，15（1）：27-33. variation in two proteinsof the endocannabinoid system
[16] DRUCKER DJ. Glucagon-like peptides：regulators of cell and their influence on body mass indexand metabolism un-
proliferation，differentiation，and apoptosis[J]. Mol Endo- der low fat diet[J]. Horm Metab Res，2007，39（5）：395-
crinol，2003，17（2）：161-171. 397.
[17] HOLST JJ. Therapy of type 2 diabetes mellitus based on [28] DE LUIS DA，GONZALEZ SAGRADO M，ALLER R，et
the actions of glucagon-like peptide-1[J]. Diabetes Metab al. Roles of G1359A polymorphism of the cannabinoid re-
Res Rev，2002，18（6）：430-441. ceptor gene（CNR1）on weight loss and adipocytokines af-
[18] KEBEDE MA，OLER AT，GREGG T，et al. SORCS1 is ter a hypocaloric diet[J]. Nutr Hosp，2011，26（2）：317-

中国药房 2020年第31卷第2期 China Pharmacy 2020 Vol. 31 No. 2 ·249 ·